USANA Health Sciences, Inc. (NYSE:USNA) was the target of a large decrease in short interest during the month of July. As of July 31st, there was short interest totalling 1,360,900 shares, a decrease of 28.4% from the June 30th total of 1,899,600 shares. Approximately 10.1% of the shares of the stock are short sold. Based on an average daily volume of 380,000 shares, the days-to-cover ratio is presently 3.6 days.
NYSE USNA traded up $1.88 on Monday, hitting $68.94. 191,283 shares of the company were exchanged, compared to its average volume of 327,251. The firm’s 50 day simple moving average is $66.62. The company has a market cap of $1.49 billion, a P/E ratio of 13.36 and a beta of 0.44. USANA Health Sciences has a 1-year low of $58.30 and a 1-year high of $134.65.
USANA Health Sciences (NYSE:USNA) last issued its quarterly earnings results on Tuesday, July 23rd. The company reported $0.91 earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of $0.93 by ($0.02). The company had revenue of $256.00 million for the quarter, compared to analyst estimates of $254.66 million. USANA Health Sciences had a return on equity of 27.22% and a net margin of 9.68%. The firm’s quarterly revenue was down 15.1% on a year-over-year basis. During the same quarter last year, the company earned $1.36 EPS. Equities research analysts anticipate that USANA Health Sciences will post 3.9 earnings per share for the current fiscal year.
Several equities research analysts have recently weighed in on USNA shares. Sidoti lowered shares of USANA Health Sciences from a “buy” rating to a “neutral” rating and set a $70.00 target price on the stock. in a report on Wednesday, July 3rd. Tigress Financial initiated coverage on shares of USANA Health Sciences in a research report on Tuesday, April 16th. They set a “buy” rating on the stock. ValuEngine upgraded shares of USANA Health Sciences from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. Pivotal Research reiterated a “buy” rating on shares of USANA Health Sciences in a research report on Wednesday, July 24th. Finally, TheStreet downgraded shares of USANA Health Sciences from a “b-” rating to a “c+” rating in a research report on Thursday, July 11th. Two investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. USANA Health Sciences presently has a consensus rating of “Buy” and an average price target of $72.50.
A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Bank of America Corp DE raised its holdings in USANA Health Sciences by 151.8% during the fourth quarter. Bank of America Corp DE now owns 34,557 shares of the company’s stock worth $4,068,000 after purchasing an additional 20,835 shares in the last quarter. Legal & General Group Plc raised its holdings in USANA Health Sciences by 6.7% during the fourth quarter. Legal & General Group Plc now owns 5,835 shares of the company’s stock worth $687,000 after purchasing an additional 367 shares in the last quarter. Amalgamated Bank purchased a new position in USANA Health Sciences during the fourth quarter worth about $223,000. Norges Bank purchased a new position in USANA Health Sciences during the fourth quarter worth about $35,531,000. Finally, Geode Capital Management LLC raised its holdings in USANA Health Sciences by 6.7% during the fourth quarter. Geode Capital Management LLC now owns 199,021 shares of the company’s stock worth $23,430,000 after purchasing an additional 12,445 shares in the last quarter. Institutional investors and hedge funds own 59.12% of the company’s stock.
USANA Health Sciences Company Profile
USANA Health Sciences, Inc develops, manufactures, and sells science-based nutritional and personal care products primarily to reduce the risk of chronic degenerative disease. The company offers USANA nutritional products that comprise essentials/CellSentials, such as vitamin and mineral supplements that provide a foundation of total body nutrition for various age groups; optimizers comprising targeted supplements that are designed to meet cardiovascular, skeletal/structural, and digestive health needs; and foods that include low-glycemic meal replacement shakes, snack bars, and other related products, which provide macro-nutrition.
Recommended Story: Blockchain
Receive News & Ratings for USANA Health Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for USANA Health Sciences and related companies with MarketBeat.com's FREE daily email newsletter.